These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Umar A, Boisseau M, Yusup A, Upur H, Bégaud B, Moore N. Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377 [Abstract] [Full Text] [Related]
44. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Mahadevan U, Loftus EV, Tremaine WJ, Sandborn WJ. Am J Gastroenterol; 2002 Apr; 97(4):910-4. PubMed ID: 12008668 [Abstract] [Full Text] [Related]
45. Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib. Bannwarth B, Ravaud P, Dougados M. J Rheumatol; 2003 Feb; 30(2):421-2. PubMed ID: 12583353 [No Abstract] [Full Text] [Related]
46. [COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary]. MMW Fortschr Med; 2001 Oct 18; 143(42):64. PubMed ID: 11697296 [No Abstract] [Full Text] [Related]
48. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Perazella MA, Tray K. Am J Med; 2001 Jul 18; 111(1):64-7. PubMed ID: 11448662 [No Abstract] [Full Text] [Related]
50. Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? Howes LG, Krum H. Drug Saf; 2002 Jul 18; 25(12):829-35. PubMed ID: 12241124 [Abstract] [Full Text] [Related]
51. Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure. Ofran Y, Bursztyn M, Ackerman Z. Am J Gastroenterol; 2001 Jun 18; 96(6):1941. PubMed ID: 11419859 [No Abstract] [Full Text] [Related]
53. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects]. Burdan F, Korobowicz A. Pol Merkur Lekarski; 2003 Apr 08; 14(82):352-5. PubMed ID: 12868201 [Abstract] [Full Text] [Related]
54. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Am J Manag Care; 2002 Oct 08; 8(15 Suppl):S414-27. PubMed ID: 12416791 [Abstract] [Full Text] [Related]
55. Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. Takeeda M, Hayashi Y, Yamato M, Murakami M, Takeuchi K. J Physiol Pharmacol; 2004 Mar 08; 55(1 Pt 2):193-205. PubMed ID: 15082878 [Abstract] [Full Text] [Related]
56. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. J Rheumatol; 2002 May 08; 29(5):1015-22. PubMed ID: 12022317 [Abstract] [Full Text] [Related]